Abstract 186P
Background
Sorafenib is a multikinase inhibitor used to treat patients with unresectable hepatocellular carcinoma (HCC); however, there is no consensus on its efficacy in patients with HCC post hepatic resection. Therefore, this meta-analysis (PROSPERO ID: CRD42019122147) assessed efficacy and safety of sorafenib in patients with HCC who underwent hepatic resection.
Methods
Using PICO framework, relevant articles were retrieved from PubMed, EMBASE, Cochrane Library and Google Scholar. Articles comparing outcomes of sorafenib treated patients with HCC who underwent resection with those not receiving sorafenib were included for the analysis The primary outcome was overall survival (OS) while disease free survival (DFS), tumor recurrence rate (TRR), mortality and safety were the secondary outcomes. Hazard ratio (HR) or risk ratio (RR) along with 95% confidence interval (CI) were calculated by fixed or random effects (FE or RE) model, based on the heterogeneity. P < 0.05 was considered significant. The effect of portal vein tumor thrombosis (PVTT) and time of initiation of sorafenib therapy on survival were assessed by subgroup analysis.
Results
A total of 10 studies with data of 589 patients (mean age 52.41 years; men: 87.28%; women: 12.72%) were included in the analysis. Sorafenib significantly prolonged OS (n = 5; FE; HR: 0.69; 95% CI; 0.52, 0.93; P =.0139), reduced TRR (n = 8; FE; RR: 0.91; 95% CI: 0.83, 0.98; P =.0187) and mortality (n = 7; FE; RR: 0.75; 95% CI: 0.63, 0.88; P =.0007) in patients with HCC following hepatic resection compared to the control group. Further, DFS in the sorafenib group was non-significantly better than the control group (n = 5; FE; HR: 0.78; 95% CI: 0.56, 1.09; P =.1462). Although, the proportion of adverse events (AEs) was higher in the sorafenib group (81.1% vs 18.9%), the AEs were tolerable. Subgroup analysis revealed sorafenib to be more effective (lower TRR and mortality) in patients without PVTT than those with PVTT.
Conclusions
Adjuvant sorafenib treatment improved survival outcomes in HCC patients post hepatic resection and had acceptable safety profile. Hence, sorafenib could be recommended as an adjuvant therapy for patients with HCC after hepatic resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Science Fund for Creative Research Groups, NSFC, China (81521091); State key infection disease project of China (2018ZX10732202-002-005); National Human Genetic Resources Sharing Service Platform (2005DKA21300);.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract